Chargement en cours...

Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

BACKGROUND: One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great clinical significance....

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Med
Auteurs principaux: Bjerrum, Jacob Tveiten, Steenholdt, Casper, Ainsworth, Mark, Nielsen, Ole Haagen, Reed, Michelle AC, Atkins, Karen, Günther, Ulrich Leonhard, Hao, Fuhua, Wang, Yulan
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2017
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5641999/
https://ncbi.nlm.nih.gov/pubmed/29032767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-017-0949-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!